847871-99-2

Usage

Uses

Used in Oncology:
Lenalidomide (hemihydrate) is used as an anti-cancer agent for the treatment of multiple myeloma, myelodysplastic syndromes, and certain types of lymphoma. It is administered orally in the form of capsules and is often used in combination with other chemotherapy drugs to enhance treatment efficacy.
Used in Pharmaceutical Industry:
Lenalidomide (hemihydrate) is used as a pharmaceutical ingredient for the development of cancer treatment medications. Its hemihydrate form provides better stability and shelf-life, making it a preferred choice for pharmaceutical formulations.
Potential side effects of lenalidomide (hemihydrate) include myelosuppression, thrombosis, and birth defects, necessitating close patient monitoring during treatment.

Upstream product

• 19171-18-7 4-NT 
• 879126-98-4 Lenalidomide 

Downstream Products

• 1608889-64-0 C₁₃H₁₃N₃O₃*C₇H₆O₄ 

Relevant academic research and scientific papers

amine to the crystal and its preparation method

The invention provides a hemihydrate crystal form V of lenalidomide, which has characteristic X diffraction ray peaks in the X-ray powder diffractogram when 2theta is 12.0+/-0.2 degrees, 13.7+/-0.2 degrees, 24.7+/-0.2 degrees and 27.5+/-0.2 degrees. The invention also provides a preparation method of the hemihydrate crystal form V of lenalidomide, which comprises the following steps: (1) dissolving lenalidomide in a polar organic solvent, wherein the polar organic solvent is selected from one or more of aliphatic sulfone solvents aliphatic amide solvents; (2) dropwisely adding the solution obtained in the step (1) into 0-30 DEG C water to precipitate the expected crystal form from the solution; and (3) separating the crystal solid obtained in the step (2). The hemihydrate crystal form of lenalidomide has the advantages of high yield, high purity and high stability.

A CRYSTALLINE FORM OF LENALIDOMIDE AND A PROCESS FOR ITS PREPARATION

The present invention relates to a novel crystalline form of lenalidomide having formula (I) and chemically known as 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione. The present invention further relates to a process for the preparation of said novel form and its use in pharmaceutical preparations for the treatment of autoimmune disease, inflammation, inflammatory disease and diseases such as cancer, in particular the management of multiple myeloma.